2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Melanoma
22
Neoplasms
6
Carcinoma, Hepatocellular
5
Stomach Neoplasms
4
Recurrence
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Cancer
4
Uveal Melanoma
3
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Liver Neoplasms
3
Colonic Neoplasms
3
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasm Metastasis
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Hodgkin Disease
2
Hematologic Neoplasms
2
Glioma
2
Glioblastoma
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Basal Cell
2
Brain Neoplasms
2
Interventions
Rituximab
416
Cyclophosphamide
348
Vincristine
173
Prednisone
172
Doxorubicin
168
Etoposide
160
Peripheral Blood Stem Cell Transplantation
114
Filgrastim
108
Lenalidomide
97
fludarabine phosphate
96
Radiotherapy
80
Cytarabine
80
Gemcitabine
73
Melphalan
66
Mycophenolic Acid
64
Cyclosporine
60
Methotrexate
59
Busulfan
57
Ifosfamide
55
Carmustine
55
fludarabine
50
Tacrolimus
50
Whole-Body Irradiation
49
Carboplatin
49
polatuzumab vedotin
44
Oxaliplatin
44
Dexamethasone
44
Antilymphocyte Serum
42
ibrutinib
40
Bendamustine Hydrochloride
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma, Large B-Cell, Diffuse
×
relatlimab
×
Clear all
NCT05255601
2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2
Completed
5 enrolled
NCT03310619
2024-04-04
PLATFORM
Celgene
Phase 1/2
Completed
62 enrolled
41 charts